Thermo Fisher Scientific Completes $2.2 Billion Registered Public Offering of Senior Notes

Thermo Fisher Scientific Completes $2.2 Billion Registered Public Offering of Senior Notes

Client News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.

WilmerHale represented Thermo Fisher Scientific Inc., a multinational biotechnology product development company, in its public offering of $1.1 billion aggregate principal amount of 4.133% Senior Notes due 2025 and $1.1 billion aggregate principal amount of 4.497% Senior Notes due 2030. Both series of notes priced at 100% of principal. The net proceeds of the offering will be used to pay a portion of the purchase price of the previously announced acquisition of QIAGEN N.V and for general corporate purposes. The offering priced on March 23, 2020 and closed on March 25, 2020.

The team consisted of Erika Robinson, Justin Ochs, Julie Hogan Rodgers, Alan Wilson and Jenny Moore.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel